A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
In the register
The register attaches this trial to Baricitinib (Olumiant) (Eli Lilly), currently at “Approved” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Completed
- Declared phase
- Phase 2/3
- Sponsor
- Eli Lilly and Company
- Participants (registry)
- 784
- Start
- September 2018
- Primary completion
- February 2021
- Study completion
- January 2025
- Last registry update
- April 2026
- Countries
- United States, Japan, Mexico, Puerto Rico, South Korea
Conditions studied: Alopecia Areata
Interventions: Baricitinib, LY3009104, Placebo
Other trials of Baricitinib (Olumiant)
Evaluating the Effectiveness and Tolerance of Baricitinib in the Treatment of Acute Alopecia Areata With Active Hair Shedding: A Prospective Open-Label Study
Baricitinib for Central Centrifugal Cicatricial Alopecia in Adults of African Descent
A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)
Retinol Binding Protein 4 Protein in Alopecia Areata Treated With Barcitinib
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
- NCT07645430Completed
Assessment of Interleukin-15 and Interferon Gamma in Alopecia Areata Before and After Baricitinib.
A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.